上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2015年
15期
14-18
,共5页
非小细胞肺癌%表皮生长因子受体%酪氨酸激酶抑制剂%突变%耐药
非小細胞肺癌%錶皮生長因子受體%酪氨痠激酶抑製劑%突變%耐藥
비소세포폐암%표피생장인자수체%락안산격매억제제%돌변%내약
non-small cell lung cancer%epidermal growth factor receptor%tyrosine kinase inhibitors%mutations%drug resistance
人类表皮生长因子受体（EGFR）是原癌基因 C-erbB1的表达产物，属于酪氨酸激酶生长因子受体家族成员之一，在人类多种实体肿瘤中过度表达，与肿瘤细胞的增殖、侵袭、转移及血管生长等有关。选择 EGFR 为靶点是近年来非小细胞肺癌（NSCLC）治疗的前沿手段，第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）吉非替尼或厄洛替尼对于复发或进展期 NSCLC 显示出较好的疗效，但仅对特定人群有效。如何规范临床应用、建立完善的疗效预测系统、探讨耐药的机制及处理策略等是临床面临的难题。本文就关于这些问题的研究进展作一综述。
人類錶皮生長因子受體（EGFR）是原癌基因 C-erbB1的錶達產物，屬于酪氨痠激酶生長因子受體傢族成員之一，在人類多種實體腫瘤中過度錶達，與腫瘤細胞的增殖、侵襲、轉移及血管生長等有關。選擇 EGFR 為靶點是近年來非小細胞肺癌（NSCLC）治療的前沿手段，第一代錶皮生長因子受體酪氨痠激酶抑製劑（EGFR-TKIs）吉非替尼或阨洛替尼對于複髮或進展期 NSCLC 顯示齣較好的療效，但僅對特定人群有效。如何規範臨床應用、建立完善的療效預測繫統、探討耐藥的機製及處理策略等是臨床麵臨的難題。本文就關于這些問題的研究進展作一綜述。
인류표피생장인자수체（EGFR）시원암기인 C-erbB1적표체산물，속우락안산격매생장인자수체가족성원지일，재인류다충실체종류중과도표체，여종류세포적증식、침습、전이급혈관생장등유관。선택 EGFR 위파점시근년래비소세포폐암（NSCLC）치료적전연수단，제일대표피생장인자수체락안산격매억제제（EGFR-TKIs）길비체니혹액락체니대우복발혹진전기 NSCLC 현시출교호적료효，단부대특정인군유효。여하규범림상응용、건립완선적료효예측계통、탐토내약적궤제급처리책략등시림상면림적난제。본문취관우저사문제적연구진전작일종술。
Epidermal growth factor receptor (EGFR) is the product of oncogene C-erbB1 and belongs to the tyrosine kinase growth factor receptor family. EGFR is overexpressed in many solid tumors, which can promote the proliferation, invading, metastasis, angiogenesis of tumor. The targeting therapy on EGFR has become the focus of clinical trials for the treatment of non-small cell lung cancer (NSCLC) and the first generation of EGFR-TKI gefitinib or erlotinib has showed a significant activity in the treatment of advanced or recurrent NSCLC, but either of them is effective only to the specific individuals. How to regulate clinical application, establish a thorough therapeutic effect evaluation system, explore the mechanism of resistance and treatment strategies have become clinical problems. This article summarizes the progress of studies on these problems.
